EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER

Translated title of the contribution: Experimental basis of a therapy-oriented pathogenetic classification of aplastic anemia in childhood

S. Burdach, R. Vohringer, D. Dilloo, K. Krauth, H. Hanenberg, U. Gobel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Growth and differentiation of hematopoietic progenitor cells is regulated by a complex network of stimulatory and inhibitory cytokines. Bone marrow failures can be due to a decrease of stimulators or an increase of inhibitors. T cells produce both, hematopoiesis stimulating and inhibiting cytokines. Therefore, a role of T cells in regulating hematopoiesis can only be assumed if the gene expression of these antagonistic acting cytokines can be differentially induced in T cells. To establish a model of selective cytokine induction, we investigated the induction of IFNγ as inhibitor and GM-CSF as stimulator of hematopoiesis in T cells. Our results showed that IFNγ mRNA accumulates in T cells which have been pre-activated via the signal transduction unit CD3, but not in unstimulated T cells. This accumulation depends on the expression of the high affinity IL2 receptor which is including the IL2 receptor α-chain (IL2Rα, CD25). In a study on children with constitutional (CAA) versus acquired aplastic (EAA) anemia, we investigated the relevance of this model for the pathogenesis of aplastic anemia in childhood. We compared the following parameters: 1. Incidence of hematopoietic progenitor cells and cloning efficiency, 2. activation status and IL2Rα expression of bone marrow T cells, 3. T cell cytokine expression profile. Our results show: 1. The relative incidence of bone marrow progenitor cells is decreased in children with CAA and normal in children with EAA. 2. Clonogenic growth of hematopoietic progenitor cells is suppressed in children with EAA. 3. Native T cells of children with CAA show an increased induction capacity of IFNγ production, however, the induction capacity in children with CAA is normal. 4. Children with EAA show an increased incidence of activated, IL2 expressing T cells in the bone marrow. Based on these results we would like to propose the following therapy-based classification of childhood aplastic anemias: Aplastic anemias type I (CAA) is due to a reduction in the progenitor cell pool. Therefore, bone marrow transplantation would be the treatment of choice. In contrast, aplastic anemias type II (EAA) are caused by immunological suppression of the progenitor cell growth. In these patients, immunosuppression or -modulation would be the treatment of choice.

Original languageGerman
Pages (from-to)201-207
Number of pages7
JournalKlinische Padiatrie
Volume206
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

Aplastic Anemia
T-Lymphocytes
Cytokines
Hematopoiesis
Hematopoietic Stem Cells
Therapeutics
Stem Cells
Interleukin-2 Receptors
Bone Marrow Cells
Incidence
Growth
Bone Marrow
Granulocyte-Macrophage Colony-Stimulating Factor
Bone Marrow Transplantation
Immunosuppression
Interleukin-2
Organism Cloning
Signal Transduction
Gene Expression
Messenger RNA

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Burdach, S., Vohringer, R., Dilloo, D., Krauth, K., Hanenberg, H., & Gobel, U. (1994). EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER. Klinische Padiatrie, 206(4), 201-207.

EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER. / Burdach, S.; Vohringer, R.; Dilloo, D.; Krauth, K.; Hanenberg, H.; Gobel, U.

In: Klinische Padiatrie, Vol. 206, No. 4, 1994, p. 201-207.

Research output: Contribution to journalArticle

Burdach, S, Vohringer, R, Dilloo, D, Krauth, K, Hanenberg, H & Gobel, U 1994, 'EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER', Klinische Padiatrie, vol. 206, no. 4, pp. 201-207.
Burdach, S. ; Vohringer, R. ; Dilloo, D. ; Krauth, K. ; Hanenberg, H. ; Gobel, U. / EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER. In: Klinische Padiatrie. 1994 ; Vol. 206, No. 4. pp. 201-207.
@article{f3f6916f250f41f69df73522b63ee828,
title = "EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER",
abstract = "Growth and differentiation of hematopoietic progenitor cells is regulated by a complex network of stimulatory and inhibitory cytokines. Bone marrow failures can be due to a decrease of stimulators or an increase of inhibitors. T cells produce both, hematopoiesis stimulating and inhibiting cytokines. Therefore, a role of T cells in regulating hematopoiesis can only be assumed if the gene expression of these antagonistic acting cytokines can be differentially induced in T cells. To establish a model of selective cytokine induction, we investigated the induction of IFNγ as inhibitor and GM-CSF as stimulator of hematopoiesis in T cells. Our results showed that IFNγ mRNA accumulates in T cells which have been pre-activated via the signal transduction unit CD3, but not in unstimulated T cells. This accumulation depends on the expression of the high affinity IL2 receptor which is including the IL2 receptor α-chain (IL2Rα, CD25). In a study on children with constitutional (CAA) versus acquired aplastic (EAA) anemia, we investigated the relevance of this model for the pathogenesis of aplastic anemia in childhood. We compared the following parameters: 1. Incidence of hematopoietic progenitor cells and cloning efficiency, 2. activation status and IL2Rα expression of bone marrow T cells, 3. T cell cytokine expression profile. Our results show: 1. The relative incidence of bone marrow progenitor cells is decreased in children with CAA and normal in children with EAA. 2. Clonogenic growth of hematopoietic progenitor cells is suppressed in children with EAA. 3. Native T cells of children with CAA show an increased induction capacity of IFNγ production, however, the induction capacity in children with CAA is normal. 4. Children with EAA show an increased incidence of activated, IL2 expressing T cells in the bone marrow. Based on these results we would like to propose the following therapy-based classification of childhood aplastic anemias: Aplastic anemias type I (CAA) is due to a reduction in the progenitor cell pool. Therefore, bone marrow transplantation would be the treatment of choice. In contrast, aplastic anemias type II (EAA) are caused by immunological suppression of the progenitor cell growth. In these patients, immunosuppression or -modulation would be the treatment of choice.",
author = "S. Burdach and R. Vohringer and D. Dilloo and K. Krauth and H. Hanenberg and U. Gobel",
year = "1994",
language = "German",
volume = "206",
pages = "201--207",
journal = "Klinische Padiatrie",
issn = "0300-8630",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - EXPERIMENTELLE GRUNDLAGEN EINER THERAPIE-ORIENTIERTEN PATHOGENETISCHEN KLASSIFIKATION DER APLASTISCHEN ANAMIE IM KINDESALTER

AU - Burdach, S.

AU - Vohringer, R.

AU - Dilloo, D.

AU - Krauth, K.

AU - Hanenberg, H.

AU - Gobel, U.

PY - 1994

Y1 - 1994

N2 - Growth and differentiation of hematopoietic progenitor cells is regulated by a complex network of stimulatory and inhibitory cytokines. Bone marrow failures can be due to a decrease of stimulators or an increase of inhibitors. T cells produce both, hematopoiesis stimulating and inhibiting cytokines. Therefore, a role of T cells in regulating hematopoiesis can only be assumed if the gene expression of these antagonistic acting cytokines can be differentially induced in T cells. To establish a model of selective cytokine induction, we investigated the induction of IFNγ as inhibitor and GM-CSF as stimulator of hematopoiesis in T cells. Our results showed that IFNγ mRNA accumulates in T cells which have been pre-activated via the signal transduction unit CD3, but not in unstimulated T cells. This accumulation depends on the expression of the high affinity IL2 receptor which is including the IL2 receptor α-chain (IL2Rα, CD25). In a study on children with constitutional (CAA) versus acquired aplastic (EAA) anemia, we investigated the relevance of this model for the pathogenesis of aplastic anemia in childhood. We compared the following parameters: 1. Incidence of hematopoietic progenitor cells and cloning efficiency, 2. activation status and IL2Rα expression of bone marrow T cells, 3. T cell cytokine expression profile. Our results show: 1. The relative incidence of bone marrow progenitor cells is decreased in children with CAA and normal in children with EAA. 2. Clonogenic growth of hematopoietic progenitor cells is suppressed in children with EAA. 3. Native T cells of children with CAA show an increased induction capacity of IFNγ production, however, the induction capacity in children with CAA is normal. 4. Children with EAA show an increased incidence of activated, IL2 expressing T cells in the bone marrow. Based on these results we would like to propose the following therapy-based classification of childhood aplastic anemias: Aplastic anemias type I (CAA) is due to a reduction in the progenitor cell pool. Therefore, bone marrow transplantation would be the treatment of choice. In contrast, aplastic anemias type II (EAA) are caused by immunological suppression of the progenitor cell growth. In these patients, immunosuppression or -modulation would be the treatment of choice.

AB - Growth and differentiation of hematopoietic progenitor cells is regulated by a complex network of stimulatory and inhibitory cytokines. Bone marrow failures can be due to a decrease of stimulators or an increase of inhibitors. T cells produce both, hematopoiesis stimulating and inhibiting cytokines. Therefore, a role of T cells in regulating hematopoiesis can only be assumed if the gene expression of these antagonistic acting cytokines can be differentially induced in T cells. To establish a model of selective cytokine induction, we investigated the induction of IFNγ as inhibitor and GM-CSF as stimulator of hematopoiesis in T cells. Our results showed that IFNγ mRNA accumulates in T cells which have been pre-activated via the signal transduction unit CD3, but not in unstimulated T cells. This accumulation depends on the expression of the high affinity IL2 receptor which is including the IL2 receptor α-chain (IL2Rα, CD25). In a study on children with constitutional (CAA) versus acquired aplastic (EAA) anemia, we investigated the relevance of this model for the pathogenesis of aplastic anemia in childhood. We compared the following parameters: 1. Incidence of hematopoietic progenitor cells and cloning efficiency, 2. activation status and IL2Rα expression of bone marrow T cells, 3. T cell cytokine expression profile. Our results show: 1. The relative incidence of bone marrow progenitor cells is decreased in children with CAA and normal in children with EAA. 2. Clonogenic growth of hematopoietic progenitor cells is suppressed in children with EAA. 3. Native T cells of children with CAA show an increased induction capacity of IFNγ production, however, the induction capacity in children with CAA is normal. 4. Children with EAA show an increased incidence of activated, IL2 expressing T cells in the bone marrow. Based on these results we would like to propose the following therapy-based classification of childhood aplastic anemias: Aplastic anemias type I (CAA) is due to a reduction in the progenitor cell pool. Therefore, bone marrow transplantation would be the treatment of choice. In contrast, aplastic anemias type II (EAA) are caused by immunological suppression of the progenitor cell growth. In these patients, immunosuppression or -modulation would be the treatment of choice.

UR - http://www.scopus.com/inward/record.url?scp=0028129937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028129937&partnerID=8YFLogxK

M3 - Article

C2 - 7967417

AN - SCOPUS:0028129937

VL - 206

SP - 201

EP - 207

JO - Klinische Padiatrie

JF - Klinische Padiatrie

SN - 0300-8630

IS - 4

ER -